This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax

09/30/14 - 09:49 AM EDT

What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?

READ FULL POST

Clovis Shares Higher on Improved Outlook for Lung Cancer Drug

09/29/14 - 12:17 PM EDT

Clovis Oncology shares are higher Monday because AstraZeneca, its direct competitor to develop a new, genetically targeted lung cancer drug, slipped this weekend.

READ FULL POST

Gilead Sciences' Next-Generation HIV Drug Hits the Mark

09/24/14 - 10:30 AM EDT

TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.

READ FULL POST

Merrimack Does Well to License Marginal Cancer Drug to Baxter

09/24/14 - 08:14 AM EDT

Baxter has a hunger for cancer drugs with hair.

READ FULL POST

Tekmira Experimental Ebola Drug Used to Treat Stricken U.S. Doctor

09/22/14 - 07:48 PM EDT

Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.

READ FULL POST

Northwest Bio's Almost-Toxic Debt Raise Responsible for Stock Slide

09/22/14 - 08:59 AM EDT

The buyers of Northwest's debt want the stock price to decline before Feb. 15, 2015, because a lower stock price also will drop the conversion price of the notes.

READ FULL POST

Ariad Director Resignation May Mean CEO Berger One Step Closer to Exit

09/19/14 - 12:05 PM EDT

Activist investor Alex Denner is gaining an ally on Ariad's Board.

READ FULL POST

SEC Slaps Biotech Hedge Fund for Short-Selling Violations

09/16/14 - 01:04 PM EDT

On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.

READ FULL POST

Avanir's Over-Priced Cough Syrup Touted for Role in Alzheimer's Agitation

09/15/14 - 10:19 AM EDT

Avanir Pharmaceuticals are surging Monday after demonstrating once again that cough syrup produces a nice, mellow high

READ FULL POST

Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal

09/12/14 - 09:43 AM EDT

Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

DOW 17,069.49 -1.73 -0.01%
S&P 500 1,976.91 -0.89 -0.04%
NASDAQ 4,498.6730 -7.1790 -0.16%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs